公开(公告)号：US20190233528A1

公开(公告)日：2019-08-01

申请号：US16264371

申请日：2019-01-31

Applicant: Pfizer Inc.

Inventor： Surabhi Srivatsa Srinivasan ,  Niranjana Aditi Nagarajan ,  Siler Panowski ,  Yoon Park ,  Tao Sai ,  Barbra Johnson SASU ,  Thomas John Van Blarcom ,  Mathilde Brunnhilde Dusseaux ,  Roman Ariel Galetto

IPC: C07K16/28 ,  C07K14/725 ,  A61K39/00 ,  A61P35/02 ,  A61P35/04

CPC classification number: C07K16/2875 ,  A61K39/001129 ,  A61K39/001138 ,  A61K2039/5156 ,  A61P35/02 ,  A61P35/04 ,  C07K14/7051 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/33

Abstract: The disclosure provides CARs (CARs) that specifically bind to CD70. The disclosure further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The disclosure further relates to therapeutic methods for use of these CARs and engineered immune cells comprising these CARs for the treatment of a condition associated with malignant cells expressing CD70 (e.g., cancer).

公开(公告)号：US10259876B2

公开(公告)日：2019-04-16

申请号：US15402760

申请日：2017-01-10

Applicant: PFIZER INC.

Inventor： Oi Kwan Wong ,  Joyce Ching Chou ,  Mathilde Brunnhilde Dusseaux ,  Julianne Smith ,  Barbra Johnson Sasu

IPC: A61K35/17 ,  C12N9/64 ,  A61K31/436 ,  C12N15/62 ,  C07K16/28 ,  C07K14/725 ,  C07K14/47 ,  A61K39/00 ,  A61K38/00

Abstract: The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making thereof, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for using these CARs and engineered immune cells for the treatment of EGFRvIII-mediated pathologies, including cancers such as glioblastoma.

公开(公告)号：US20220227874A1

公开(公告)日：2022-07-21

申请号：US17586321

申请日：2022-01-27

Applicant: Pfizer Inc.

Inventor： Oi Kwan Wong ,  Joyce Ching Chou ,  Mathilde Brunnhilde Dusseaux ,  Julianne Smith ,  Barbra Johnson Sasu

IPC: C07K16/28 ,  C07K14/47 ,  C07K14/725

Abstract: The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making thereof, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for using these CARs and engineered immune cells for the treatment of EGFRvIII-mediated pathologies, including cancers such as glioblastoma.

公开(公告)号：US11267892B2

公开(公告)日：2022-03-08

申请号：US16255348

申请日：2019-01-23

Applicant: Pfizer Inc.

Inventor： Oi Kwan Wong ,  Joyce Ching Chou ,  Mathilde Brunnhilde Dusseaux ,  Julianne Smith ,  Barbra Johnson Sasu

IPC: A61K35/17 ,  C12N9/64 ,  A61K31/436 ,  C07K16/28 ,  C07K14/47 ,  C07K14/725 ,  A61K38/00 ,  A61K39/00

Abstract: The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making thereof, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for using these CARs and engineered immune cells for the treatment of EGFRvIII-mediated pathologies, including cancers such as glioblastoma.